CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$3.31
0.09 (2.80%)
▲
5d:
+5.41%
30d:
+20.8%
90d:
+21.25%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CRON shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CRON shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $3.31, which is considered extended relative to its 30-day fair value range of $2.75 to $3.13. The stock's valuation (Forward PE: 20.9) is in line with its historical norms (21.0). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This pessimistic expectation contrasts with the company's recent 126.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is approaching resistance at $3.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRON scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.55. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is approaching resistance at $3.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRON scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.55. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.75 -
$3.13
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
14.3%
Protect Your Profits
Holding CRON? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.8% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 23.0% above Wall St target ($2.55)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.75 -
$3.13
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.99
Resistance Level
$3.32
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.91
Wall Street Target
$2.55
(-23.0%)
Revenue Growth (YoY)
58.4%
Earnings Growth (YoY)
126.8%
Profit Margin
39.1%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
20.9 vs 21.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$3.30
(0%)
2-Year Target
$3.30
(0%)
3-Year Target
$3.29
(-1%)
3-Yr Target (if PE normalizes)
(PE: 21→21)
$3.30
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.9, Growth: -28.3%)
$2.41
(+-27%)
Base:
(SPY PE: 20.1, Growth: -28.3%)
$2.32
(-30%)
Bear:
(PE: 17.1, Growth: -28.3%)
$1.97
(-41%)
📈
Valuation based on Current Earnings
Trailing PE: 16.95 | Current EPS (TTM): $0.19
Bull Case
$2.95
(-11%)
Analyst growth -16.7%, PE expands to 18.6
Base Case
$2.68
(-19%)
Market implied -16.7%, PE stable at 17.0
Bear Case
$2.19
(-34%)
Severe decline -20.0%, PE contracts to 14.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.9 to 21.0
Stabilization Target:
$3.32
(+0.4%)
PE Expansion Potential:
+0.4%
Share & Embed Analysis
Last updated: August 24, 2026 8:03 AM ET
Data refreshes hourly during market hours. Next update: 9:03 AM
Data refreshes hourly during market hours. Next update: 9:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
